<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-four children between 3 and 14 years of age with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were studied at the University of Nigeria Teaching Hospital, Enugu, Nigeria from November 1991 to March 1995 </plain></SENT>
<SENT sid="1" pm="."><plain>Mean age at presentation was 7.6 years with a male:female ratio of 2.7:1 </plain></SENT>
<SENT sid="2" pm="."><plain>Eighty-six per cent of the patients lived in a rural area </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 23 (52%) from Enugu State, 16 were living in contiguous local government areas with ten clustered round the middle of the year </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the children were of the lowest socio-economic class, 75% of them being in class V </plain></SENT>
<SENT sid="5" pm="."><plain>The incidence of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was higher during the dry season and the period of high <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> transmission (p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0000735" disease_type="Neoplastic Process" abbrv="">Abdominal tumour</z:e> was the commonest mode of presentation (32% of patients) </plain></SENT>
<SENT sid="7" pm="."><plain>Thirty-six patients were treated with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, Oncovin, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and predinisolone (COMP), five received <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> alone and three had <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (<z:chebi fb="1" ids="17361">CMP</z:chebi>) </plain></SENT>
<SENT sid="8" pm="."><plain>Multi-drug regimens achieved better results which were significantly unrelated to the number of cycles of therapy received </plain></SENT>
<SENT sid="9" pm="."><plain>Overall, 48% had complete and 35% partial remission, 23% relapsed and 16 (36%) patients died </plain></SENT>
<SENT sid="10" pm="."><plain>The epidemiological characteristics of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in this study were similar to those in other tropical regions </plain></SENT>
</text></document>